{"id":"W4321606338","doi":"10.1016/s2213-2600(22)00504-5","title":"Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials","year":2023,"lang":"en","type":"article","venue":"The Lancet Respiratory Medicine","topic":"Cystic Fibrosis Research Advances","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Center for Advancing Translational Sciences; NIHR Leicester Clinical Research Facility; National Institute for Health and Care Research; National Institutes of Health; Vertex Pharmaceuticals; Medical Research Council; Cystic Fibrosis Foundation Therapeutics; Mylan; Cystic Fibrosis Foundation","keywords":"Ivacaftor; Cystic fibrosis; Medicine; Cystic fibrosis transmembrane conductance regulator; Internal medicine; Clinical endpoint; Randomized controlled trial; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002941474,0.00174666,0.003949867,0.0005550319,0.0003939279,0.001404015,0.001007415,0.003073571,0.005152953],"category_scores_gemma":[0.003477619,0.0008709988,0.003025048,0.0004521912,0.001604825,0.001779071,0.0004426807,0.003495445,0.0008118632],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008949835,"about_ca_system_score_gemma":0.0009989481,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001064934,"about_ca_topic_score_gemma":0.001927647,"domain_scores_codex":[0.9987847,0.0005844688,0.0001391027,0.0002088572,0.0001218175,0.0001611052],"domain_scores_gemma":[0.9984614,0.0005398186,0.000514373,0.00009693083,0.00009539284,0.0002921578],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9654155,0.002146218,0.0005107977,0.0023462,0.002448497,0.00004430941,0.00006748638,0.0002238283,0.003454566,0.0001616947,0.0009594059,0.02222156],"study_design_scores_gemma":[0.9616011,0.03469423,0.001365492,0.0001433978,0.0008003511,0.00003980959,0.00002317423,0.0001426479,0.0002881337,0.0001557958,0.0007248749,0.00002087926],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9082119,0.07651269,0.001850723,0.002167379,0.001524936,0.004732172,0.001560371,0.0002058802,0.003234002],"genre_scores_gemma":[0.965386,0.02190955,0.00245462,0.001759799,0.0009112243,0.00365426,0.001120746,0.00003865251,0.002765044],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005152953,"threshold_uncertainty_score":0.01723832,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08485193142621349,"score_gpt":0.4004895064889591,"score_spread":0.3156375750627456,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}